トラネキサム酸の世界市場 (～2035年)：製剤タイプ・用途・流通経路・エンドユーザー・剤形・地域別

世界のトラネキサム酸の市場規模は、2024年の10億3,747万米ドルから、予測期間中はCAGR 5.38%で大きく成長し、2035年には18億6,199万米ドルの規模に達すると予測されています。

世界のトラネキサム酸市場は医療、製薬、美容分野において効果的な止血剤への需要が高まっていることを主な要因として、急速に拡大しています。トラネキサム酸は、手術、外傷、月経異常による過剰出血の予防に頻繁に使用されるようになっており、病院、クリニック、在宅医療、救急医療現場において広く採用が進んでいます。さらに、トラネキサム酸が皮膚科および美容分野、特に色素沈着治療において持つ利点が広く認識されるようになったことで、市場は拡大しています。

また、薬剤の製剤技術および送達メカニズムにおける技術革新により、バイオアベイラビリティおよび治療効果が向上し、市場環境は大きく変化しています。リポソームやナノ粒子ベースの製剤など、革新的なトラネキサム酸製剤は、治療効果を高めつつ、副作用の軽減にも寄与しています。さらに、他の有効成分を組み合わせた併用療法の開発によって、医療および美容用途におけるトラネキサム酸の適応範囲が拡大していることも、市場成長を後押ししています。

地域別分析

世界のトラネキサム酸市場において、北米は、先進的な医療インフラ、手術件数の多さ、出血管理への意識向上を背景に、支配的な地域となっています。米国とカナダは、外傷関連の負傷件数の増加、規制政策の支援、外科的治療の拡大により、トラネキサム酸の採用において最前線を走っています。

欧州は成熟した規制の整った地域であり、広範な臨床利用、政府からの強力な支援、確立された製薬製造能力を特徴としています。欧州医薬品庁（EMA）および各国の規制当局によって、トラネキサム酸はさまざまな医療用途に認可されており、これにより医療機関における標準化された使用が保証されています。アジア太平洋地域は急速な成長を遂げており、製薬生産の拡大、外傷発生件数の多さ、母子保健への関心の高まり、手術件数の増加などが成長を後押ししています。

当レポートでは、世界のトラネキサム酸の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 成長パラメータマップ：促進因子
  • 外科手術の増加
  • 外傷症例の増加
  • 過多月経の罹患率増加
• 課題
  • 厳格な規制要件
  • 新しい製剤の研究開発費の高さ
• 市場機会マップ
  • 低侵襲性および非外科的治療オプションの需要の高まり
  • 新興市場の未開拓の可能性

第5章 市場要因分析

• ポーターのファイブフォースモデル
• COVID-19の影響分析

第6章 世界のトラネキサム酸市場：製剤タイプ別

• 経口剤
• 注射剤
• 局所剤

第7章 世界のトラネキサム酸市場：用途別

• 月経過多
• 外科的出血制御
• 外傷・怪我
• 遺伝性血管性浮腫（HAE）
• 産後出血
• その他

第8章 世界のトラネキサム酸市場：エンドユーザー別

• 病院・クリニック
• 外来手術センター
• その他

第9章 世界のトラネキサム酸市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • その他
• その他の地域
  • 中東
  • アフリカ
  • ラテンアメリカ

第10章 競合情勢

• 市場シェア分析
• 競合ダッシュボード
• 主要なディスラプターとイノベーター
• 市場リーダーが採用している戦略
• 主な展開と成長戦略

第11章 企業プロファイル

• PFIZER INC
• FRESENIUS KABI USA, LLC
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• MAXWELLIA LTD.
• AUROBINDO PHARMA USA
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• APOTEX INC.
• FERRING PHARMACEUTICALS
• NORDIC PHARMA, INC
• EXELA PHARMA SCIENCES LLC

第12章 データの引用

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 3 GLOBAL TRANEXAMIC ACID MARKET, FOR ORAL, BY REGION, 2019-2035 (USD MILLION)
• TABLE 4 GLOBAL TRANEXAMIC ACID MARKET, FOR INJECTABLE, BY REGION, 2019-2035 (USD MILLION)
• TABLE 5 GLOBAL TRANEXAMIC ACID MARKET, FOR TROPICAL, BY REGION, 2019-2035 (USD MILLION)
• TABLE 6 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 7 GLOBAL TRANEXAMIC ACID MARKET, FOR MENORRHAGIA, BY REGION, 2019-2035 (USD MILLION)
• TABLE 8 GLOBAL TRANEXAMIC ACID MARKET, FOR SURGICAL BLEEDING CONTROL, BY REGION, 2019-2035 (USD MILLION)
• TABLE 9 GLOBAL TRANEXAMIC ACID MARKET, FOR TRAUMA AND INJURY, BY REGION, 2019-2035 (USD MILLION)
• TABLE 10 GLOBAL TRANEXAMIC ACID MARKET, FOR HEREDITARY ANGIOEDEMA (HAE), BY REGION, 2019-2035 (USD MILLION)
• TABLE 11 GLOBAL TRANEXAMIC ACID MARKET, FOR POSTPARTUM HEMORRHAGE, BY REGION, 2019-2035 (USD MILLION)
• TABLE 12 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 13 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 14 GLOBAL TRANEXAMIC ACID MARKET, FOR HOSPITALS & CLINICS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 15 GLOBAL TRANEXAMIC ACID MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 16 GLOBAL TRANEXAMIC ACID MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD MILLION)
• TABLE 17 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2019-2035 (USD MILLION)
• TABLE 18 NORTH AMERICA TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 19 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 20 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 21 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 22 US: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 23 US: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 24 US: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 25 CANADA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 26 CANADA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 27 CANADA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 28 EUROPE: TRANEXAMIC ACIDS MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 29 EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 30 EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 31 EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 32 GERMANY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 33 GERMANY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 34 GERMANY: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 35 UK: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 36 UK: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 37 UK: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 38 FRANCE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 39 FRANCE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 40 FRANCE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 41 ITALY: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 42 ITALY: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 43 ITALY: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 44 SPAIN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 45 SPAIN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 46 SPAIN: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 47 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 48 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 49 REST OF EUROPE: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 50 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 51 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 52 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 53 ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 54 CHINA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 55 CHINA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 56 CHINA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 57 INDIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 58 INDIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 59 INDIA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 60 JAPAN: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 61 JAPAN: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 62 JAPAN: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 63 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 64 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 65 SOUTH KOREA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 66 AUSTRALIA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 67 AUSTRALIA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 68 AUSTRALIA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 69 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 70 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 71 REST OF ASIA-PACIFIC: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 72 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
• TABLE 73 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 74 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 75 REST OF THE WORLD: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 76 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 77 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 78 MIDDLE EAST: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 79 AFRICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 80 AFRICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 81 AFRICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 82 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2019-2035 (USD MILLION)
• TABLE 83 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
• TABLE 84 LATIN AMERICA: TRANEXAMIC ACID MARKET, BY END USER, 2019-2035 (USD MILLION)
• TABLE 85 MERGER AND ACQUISITION
• TABLE 86 PRODUCT LAUNCH
• TABLE 87 PFIZER INC: PRODUCTS OFFERED
• TABLE 88 FRESENIUS KABI USA, LLC: PRODUCTS OFFERED
• TABLE 89 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
• TABLE 90 MAXWELLIA LTD.: PRODUCTS OFFERED
• TABLE 91 AUROBINDO PHARMA USA: PRODUCTS OFFERED
• TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
• TABLE 93 APOTEX INC.: PRODUCTS OFFERED
• TABLE 94 FERRING PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 95 NORDIC PHARMA, INC: PRODUCTS OFFERED
• TABLE 96 EXELA PHARMA SCIENCES LLC: PRODUCTS OFFERED

LIST OF FIGURES

• FIGURE 1 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL TRANEXAMIC ACID MARKET, 2024
• FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY FORMULATION TYPE, 2024
• FIGURE 3 GLOBAL TRANEXAMIC ACID ANALYSIS, BY APPLICATION, 2024
• FIGURE 4 GLOBAL TRANEXAMIC ACID ANALYSIS, BY END USER, 2024
• FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET ANALYSIS, BY REGION, 2024
• FIGURE 1 GLOBAL TRANEXAMIC ACID MARKET: STRUCTURE
• FIGURE 2 GLOBAL TRANEXAMIC ACID MARKET: MARKET GROWTH FACTOR ANALYSIS (2019-2035)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2019-2035)
• FIGURE 4 PORTER'S FIVE FORCES MODEL: GLOBAL TRANEXAMIC ACID MARKET
• FIGURE 5 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE, 2024 & 2035 (USD MILLION)
• FIGURE 7 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY FORMULATION TYPE, 2024
• FIGURE 8 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 9 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION)
• FIGURE 10 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY APPLICATION, 2024
• FIGURE 11 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS
• FIGURE 12 GLOBAL TRANEXAMIC ACID MARKET, BY END USER, 2024 & 2035 (USD MILLION)
• FIGURE 13 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY END USER, 2024
• FIGURE 14 GLOBAL TRANEXAMIC ACID MARKET, BY REGION, 2024 & 2035 (USD MILLION)
• FIGURE 15 GLOBAL TRANEXAMIC ACID MARKET SHARE (%), BY REGION, 2024
• FIGURE 16 NORTH AMERICA: TRANEXAMIC ACID MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 17 NORTH AMERICA: TRANEXAMIC ACID MARKET SHARE (%), BY COUNTRY, 2024
• FIGURE 18 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 19 EUROPE: TRANEXAMIC ACIDS MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 20 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 21 ASIA-PACIFIC: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 (%)
• FIGURE 22 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION)
• FIGURE 23 REST OF THE WORLD: TRANEXAMIC ACID MARKET SHARE, BY REGION, 2024 (%)
• FIGURE 24 GLOBAL TRANEXAMIC ACID MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024
• FIGURE 25 COMPETITOR DASHBOARD: GLOBAL TRANEXAMIC ACID MARKET
• FIGURE 26 PFIZER INC: SWOT ANALYSIS
• FIGURE 27 FRESENIUS KABI USA, LLC: SWOT ANALYSIS
• FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
• FIGURE 29 MAXWELLIA LTD: SWOT ANALYSIS
• FIGURE 30 AUROBINDO PHARMA USA: SWOT ANALYSIS
• FIGURE 31 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
• FIGURE 32 APOTEX INC.: SWOT ANALYSIS
• FIGURE 33 FERRING PHARMACEUTICALS: SWOT ANALYSIS
• FIGURE 34 NORDIC PHARMA, INC: SWOT ANALYSIS
• FIGURE 35 EXELA PHARMA SCIENCES LLC: SWOT ANALYSIS

Global Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

Market Overview

The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024.

The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation.

The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth as a result of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients.

Market Segmentation Analysis

In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention.

In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for haemorrhage management is the reason for this growth.

Analysis of the Region

In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions.

Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments.

Major Players

Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
• 1.2 MARKET ATTRACTIVENESS ANALYSIS
• 1.3 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE
• 1.4 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION
• 1.5 GLOBAL TRANEXAMIC ACID MARKET, BY END USER
• 1.6 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research Data Flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research Data Flow:
  • 3.5.2 Primary Research: Number of Interviews conducted
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Type
• 3.8 DATA MODELING
  • 3.8.1 Microeconomic Factor Analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 GROWTH PARAMETERS MAPPED - DRIVERS
  • 4.2.1 Increasing Surgical Procedures
  • 4.2.2 Growing Prevalence of Trauma Cases
  • 4.2.3 Growing Prevalence of Heavy Menstrual Bleeding (HMB)
• 4.3 WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
  • 4.3.1 Stringent Regulatory Requirements
  • 4.3.2 High R&D Costs for New Formulations
• 4.4 MARKET OPPORTUNITIES MAPPED
  • 4.4.1 Rising Demand for Minimally Invasive & Non-Surgical Treatment Options
  • 4.4.2 Untapped Potential in Emerging Markets

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 Bargaining Power of Suppliers
  • 5.1.2 Bargaining Power of Buyers
  • 5.1.3 Threat of New Entrants
  • 5.1.4 Threat of Substitutes
  • 5.1.5 Intensity of Rivalry
• 5.2 COVID-19 IMPACT ANALYSIS
  • 5.2.1 Impact on R & D
  • 5.2.2 Impact on Supply Chain
  • 5.2.3 Impact on Pricing

6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE

• 6.1 INTRODUCTION
• 6.2 ORAL
• 6.3 INJECTABLE
• 6.4 TROPICAL

7 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 MENORRHAGIA
• 7.3 SURGICAL BLEEDING CONTROL
• 7.4 TRAUMA AND INJURY
• 7.5 HEREDITARY ANGIOEDEMA (HAE)
• 7.6 POSTPARTUM HEMORRHAGE
• 7.7 OTHERS

8 GLOBAL TRANEXAMIC ACID MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & CLINICS
• 8.3 AMBULATORY SURGICAL CENTERS
• 8.4 OTHERS

9 GLOBAL TRANEXAMIC ACID MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 UK
  • 9.3.3 FRANCE
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 MARKET SHARE ANALYSIS, 2024
• 10.3 COMPETITION DASHBOARD
  • 10.3.1 PRODUCT PORTFOLIO
  • 10.3.2 REGIONAL PRESENCE
  • 10.3.3 STRATEGIC ALLIANCES
  • 10.3.4 INDUSTRY EXPERIENCES
• 10.4 WHO ARE THE MAJOR DISRUPTORS & INNOVATORS
• 10.5 WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 Merger and Acquisition
  • 10.6.2 Product launch

11 COMPANY PROFILES

• 11.1 PFIZER INC
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 Key Strategy
• 11.2 FRESENIUS KABI USA, LLC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 Key Strategy
• 11.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 Key Strategy
• 11.4 MAXWELLIA LTD.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 PRODUCTS OFFERED
  • 11.4.3 KEY DEVELOPMENTS
  • 11.4.4 SWOT ANALYSIS
  • 11.4.5 Key Strategy
• 11.5 AUROBINDO PHARMA USA
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 PRODUCTS OFFERED
  • 11.5.3 KEY DEVELOPMENTS
  • 11.5.4 SWOT ANALYSIS
  • 11.5.5 Key Strategy
• 11.6 SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 Key Strategy
• 11.7 APOTEX INC.
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 PRODUCTS OFFERED
  • 11.7.3 KEY DEVELOPMENTS
  • 11.7.4 SWOT ANALYSIS
  • 11.7.5 Key Strategy
• 11.8 FERRING PHARMACEUTICALS
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 PRODUCTS OFFERED
  • 11.8.3 KEY DEVELOPMENTS
  • 11.8.4 SWOT ANALYSIS
  • 11.8.5 Key Strategy
• 11.9 NORDIC PHARMA, INC
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 PRODUCTS OFFERED
  • 11.9.3 KEY DEVELOPMENTS
  • 11.9.4 SWOT ANALYSIS
  • 11.9.5 Key Strategy
• 11.10 EXELA PHARMA SCIENCES LLC
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 PRODUCTS OFFERED
  • 11.10.3 KEY DEVELOPMENTS
  • 11.10.4 SWOT ANALYSIS
  • 11.10.5 Key Strategy

12 DATA CITATIONS